Nuvation Bio/$NUVB
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Nuvation Bio
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
Ticker
$NUVB
Sector
Primary listing
NYSE
Employees
291
Headquarters
Website
Nuvation Bio Metrics
BasicAdvanced
$1.7B
-
-$0.64
1.64
-
Price and volume
Market cap
$1.7B
Beta
1.64
52-week high
$5.55
52-week low
$1.54
Average daily volume
8.8M
Financial strength
Current ratio
8.477
Quick ratio
8.262
Long term debt to equity
15.361
Total debt to equity
17.659
Interest coverage (TTM)
-32.82%
Profitability
EBITDA (TTM)
-231.55
Gross margin (TTM)
54.26%
Net profit margin (TTM)
-813.07%
Operating margin (TTM)
-870.98%
Revenue per employee (TTM)
$90,000
Management effectiveness
Return on assets (TTM)
-24.82%
Return on equity (TTM)
-52.49%
Valuation
Price to revenue (TTM)
62.504
Price to book
5.17
Price to tangible book (TTM)
5.37
Price to free cash flow (TTM)
-8.788
Free cash flow yield (TTM)
-11.38%
Free cash flow per share (TTM)
-0.56
Growth
Revenue change (TTM)
1,137.19%
Earnings per share change (TTM)
-71.24%
3-year earnings per share growth (CAGR)
8.12%
What the Analysts think about Nuvation Bio
Analyst ratings (Buy, Hold, Sell) for Nuvation Bio stock.
Bulls say / Bears say
FDA approval of Ibtrozi (taletrectinib) for ROS1+ NSCLC puts NUVB into a new commercial phase, with RBC Capital Markets estimating potential peak revenues up to $640 million by 2034 (Reuters)
The early launch has shown strong momentum; 70 patients started Ibtrozi within seven weeks post-approval and the product earned $1.2 million in revenue in Q2 despite just 13 business days of sales (Business Wire)
Solid financial position with $607.7 million in cash, cash equivalents, and marketable securities as of June 30, 2025, plus $200 million in non-dilutive financing, is expected to fund operations into 2026 (Business Wire)
Even after FDA approval, NUVB shares dropped 17.4 percent to $2.09, revealing significant investor caution regarding the product launch and labeling clarity (Reuters)
A net loss of $59.0 million in Q2 2025 and high SG&A costs of $38.5 million highlight ongoing profitability issues for this newly commercial-stage company (Business Wire)
Market penetration may be limited by incumbent players—Bristol-Myers Squibb’s Augtyro, Pfizer’s Xalkori, and Roche’s Rozlytrek are already established in the ROS1+ NSCLC segment (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2025.
Nuvation Bio Financial Performance
Revenues and expenses
Nuvation Bio Earnings Performance
Company profitability
Nuvation Bio News
AllArticlesVideos
Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma
Business Wire2 weeks ago
Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025
Business Wire2 weeks ago
Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Nuvation Bio stock?
Nuvation Bio (NUVB) has a market cap of $1.7B as of November 06, 2025.
What is the P/E ratio for Nuvation Bio stock?
The price to earnings (P/E) ratio for Nuvation Bio (NUVB) stock is 0 as of November 06, 2025.
Does Nuvation Bio stock pay dividends?
No, Nuvation Bio (NUVB) stock does not pay dividends to its shareholders as of November 06, 2025.
When is the next Nuvation Bio dividend payment date?
Nuvation Bio (NUVB) stock does not pay dividends to its shareholders.
What is the beta indicator for Nuvation Bio?
Nuvation Bio (NUVB) has a beta rating of 1.64. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.